Engineering dynamics of growth factors and other therapeutic ligands

Biotechnology and Bioengineering

Volumn 52, Issue 1, 1996, Pages 61-80

  Lauffenburger, Douglas A ^a,b   Chu, Lily ^a   French, Anthony ^a   Oehrtman, Gregory ^a   Reddy, Cartikeya ^a   Wells, Alan ^c   Niyogi, Salil ^d   Wiley, H Steven ^e  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c University of Alabama at Birmingham   (United States)

^d OAK RIDGE NATIONAL LABORATORY   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

cell engineering; cytokine ligands; growth factors; mammalian cells; receptors; trafficking

Indexed keywords

AMINO ACIDS; GROWTH KINETICS; HEALTH CARE; PHYSIOLOGY; TISSUE;

AUTOCRINE CELL SYSTEMS; CELL ENGINEERING; CELLULAR ENDOCYTIC TRAFFICKING; GROWTH FACTORS; MAMMALIAN CELLS; MOLECULAR HEALTH CARE; MOLECULAR MEDICINE; PEPTIDE; RECEPTOR BINDING CYTOKINE LIGANDS; THERAPEUTIC LIGANDS;

CELLS;

CELL SURFACE RECEPTOR; CYTOKINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; LIGAND; RECOMBINANT EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA;

ANIMAL CELL; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSPORT; CONFERENCE PAPER; CONTROLLED STUDY; ENDOCYTOSIS; FIBROBLAST CULTURE; GENE THERAPY; GENETIC TRANSFECTION; MATHEMATICAL MODEL; MITOGENESIS; MOUSE; NONHUMAN; RECEPTOR BINDING; RECEPTOR OCCUPANCY; RECOMBINANT GENE; SIGNAL TRANSDUCTION;

EID: 0030571213     PISSN: 00063592     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0290(19961005)52:1<61::AID-BIT6>3.0.CO;2-X     Document Type: Conference Paper

References (79)

1. Axelrod, J., Read, M., Brinkhous, K., Verma. I. 1990. Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs. Proc. Natl. Acad. Sci. USA 87: 5173-5177.
2. Barrandon, Y., Green, H. 1987. Cell migration is essential for sustained growth of keratinocyte colonies: the roles of transforming growth factor-α and epidermal growth factor. Cell 50: 1131-1137.
3. Bennett, N., Schultz, G. 1993. Growth factors and wound healing: Part II. Role in normal and chronic wound healing. Am. J. Surg. 166: 74-81.
4. Brenner, D., Koch. K., Leffert, H. 1989. Transforming growth factor-α stimulates proto-oncogene c-jun expression and a mitogenic program in primary cultures of adult rat hepatocytes. DNA 8: 279-285.
5. Buckley, A., Davidson, J., Kamerath, C., Wolt, T., Woodward, S. 1985. Sustained release of epidermal growth factor accelerates wound repair. Proc. Natl. Acad. Sci. USA 82: 7340-7344.
6. Campbell, I., Baron, M., Cooke, R., Dudgeon, T., Fallon, A., Harvey, T., Tappin, M. 1990. Structure-function relationships in EGF and TGFα. Biochem. Pharmacol. 40: 35-40.
7. Carpenter, G., Wahl, M. 1990. The epidermal growth factor family, pp. 69-171. In: M. Sporn and A. Roberts (eds): Peptide growth factors and their receptors. Springer-Verlag, Berlin.
8. Castilla, A., Prieto, J., Fausto, N. 1991. Transforming growth factors beta 1 and alpha in chronic liver disease. N. Engl. J. Med. 324: 933-940.
9. Chen, W., Lazar, C., Lund, K., Welsh, J., Chang, C., Walton, G., Der, C., Wiley, H. S., Gill, G. N., Rosenfeld, M. G. 1989. Functional independence of the epidermal growth factor receptor from a domain required for ligand-induced internalization and calcium regulation. Cell 59: 33-43.
10. Chu, L., Wiley, H. S., Lauffenburger, D. A. 1995. Potential for enhanced ligand transport through tissue via 'endocytic relay': mathematical model and analysis. Tissue Eng. 2: 17-38.
11. Cima, L. G. 1994. Polymer substrates for controlled biological interaction's. J. Cell. Biochem. 56: 155-161.
12. Cima, L. G., Ingber, D., Vacanti, J., Langer, R. 1991. Hepatocyte culture on biodegradable polymeric substrates. Biotech. Bioeng. 38: 145-158.
13. Cima, L. G., Langer, R. 1993. Engineering human tissue. Chem. Eng. Prog. June: 46-54.
14. Claret, E., Renversez, J.-C., Zheng, X., Bonnefoix, T., Sotto, J.-J. 1992. Valid estimation of IL-2 secretion by PHA-stimulated T-cell clones absolutely requires the use of anti-CD25 monoclonal antibody to prevent IL-2 consumption. Immunol. Lett. 33: 179-186.
15. Decker, S. 1990. Epidermal growth factor and transforming growth factor-alpha induce differential processing of the epidermal growth factor receptor. Biochem. Biophys. Res. Commun. 166: 615-621.
16. Derynck, R. 1992. The physiology of the transforming growth factor α. Adv. Cancer Res. 58: 27-52.
17. Ebner, R., Derynck, R. 1991. Epidermal growth factor and transforming growth factor-α: differential intracellular routing and processing of ligand receptor complexes. Cell Regul. 2: 599-612.
18. Eming, S., Lee, J., Snow, R., Tompkins, R., Yarmush, M., Morgan, J. 1995. Genetically-modified human epidermis overexpressing PDGF-A directs the development of a cellular and vascular connective tissue stroma when transplanted to athymic mice. J. Invest. Derm. 105: 756-770.
19. Forsten, K., Lauffenburger, D. A. 1992a. Autocrine ligand binding to cell receptors: mathematical analysis of competition by solution decoys. Biophys. J. 61: 518-529.
20. Forsten, K., Lauffenburger, D. A. 1992b. Interrupting autocrine ligand/receptor binding: comparison between receptor blockers and ligand decoys. Biophys. J. 63: 857-861.
21. Forsten, K., Lauffenburger, D. A. 1994a. Probability of autocrine ligand capture by cell surface receptors: implications for ligand secretion measurements. J. Comp. Biol. 1: 15-23.
22. Forsten, K., Lauffenburger, D. A. 1994b. The role of low-affinity interleukin-2 receptors in autocrine ligand binding: alternative mechanisms for enhanced binding effect. Mol. Immunol. 31: 739-751.
23. French, A. 1995. Experimental and modeling studies of intracellular sorting of epidermal growth factor family ligands, Ph.D. thesis, University of Illinois at Urbana-Champaign, Urbana, IL, USA.
24. French, A., Sudlow, G., Wiley, H. S., Lauffenburger, D. A. 1994. Postendocytic trafficking of epidermal growth factor-receptor complexes is mediated through saturable and specific endosomal interactions. J. Biol. Chem. 269: 15749-15755.
25. French, A., Tadaki, D., Niyogi, S. K., Lauffenburger, D. A. 1995. Intracellular trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand interaction. J. Biol. Chem. 270: 4334-4340.
26. Gan, B., Hollenberg, M., MacCannell, K., Lederis, K., Winkler, M., Derynck, R. 1987. Distinct vascular actions epidermal growth factor-uragastrone and transforming growth factor-α. J. Pharmacol. Exp. Ther. 242: 331-337.
27. Gonzalez, F., Swales, L., Bejsovec, A., Skaer, H., Martinez-Arias, A. 1991. Secretion and movement of wingless protein in the epidermis of the Drosophila embryo. Mech. Devel. 35: 43-54.
28. Gossen, M., Bujard, H. 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89: 5547-5551.
29. Harris, E. D. 1990. Rheumatoid arthritis: pathophysiology and implications for therapy. N. Engl. J. Med. 322: 1277-1289.
30. Herbst, J., Opresko, L., Walsh, B., Lauffenburger, D. A., Wiley, H. S. 1994. Regulation of postendocytic trafficking of the epidermal growth factor receptor through endosomal retention. J. Biol. Chem. 269: 12865-12873.
31. Ibbotson, K., Harrod, J., Gowen, M., D'Souza, S., Smith, D., Winkler, M., Derynck, R., Mundy, G. 1986. Human recombinant transforming growth factor-α stimulates bone resorption and inhibits formation in vitro. Proc. Natl. Acad. Sci. USA 83: 2228-2232.
32. Jain, R. 1989. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl. Cancer Inst. 81: 570-576.
33. King, L., Gates, R., Stoscheck, C., Nanney, L. 1990. The EGF/TGFα receptor in skin. J. Invest. Dermatol. 94: 164S-170S.
34. King, R., Jones, M., Parviz, M. 1989. Regulation of lung cell proliferation by polypeptide growth factors. Am. J. Physiol. 257: L23-L38.
35. Knauer, D., Wiley, H. S., Cunningham, D. 1984. Relationship between EGF-receptor occupancy and mitogenic response: quantitative analysis using a steady-state model system. J. Biol. Chem. 259: 5623-5631.
36. Korc, M., Finman, J. 1989. Attenuated processing of epidermal growth factor in the face of marked degradation of transforming growth factor-α. J. Biol. Chem. 264: 14990-14999.
37. Korc, M., Haussler, C., Trookman, N. 1987. Divergent effects of epidermal growth factor and transforming growth factors on a human endometrial carcinoma cell line. Cancer Res. 47: 4909-4914.
38. Kubuji, D., Fine, L. 1989. Physiology and cell biology update: polypeptide growth factors and their relation to renal disease. Am. J. Kidney Dis. 14: 61-73.
39. Kulkarni, G., McCulloch, C. 1994. Serum deprivation induces apoptotic cell death in a subset of Balb 3T3 fibroblasts. J. Cell Sci. 107: 1169-1179.
40. Kung, A., Baughman, R., Larrick, J. (eds.) 1993. Therapeutic proteins: pharmacokinetics and pharmacodynamics. W. H. Freeman, New York.
41. Langer, R., Vacanti, J. 1993. Tissue engineering. Science 260: 920-926.
42. Lauffenburger, D. A., Linderman, J. 1993. Receptors: models for binding, trafficking, and signaling. Oxford University Press, New York.
43. Linderman, J., Lauffenburger, D. A. 1988. Analysis of intracellular receptor/ligand sorting in endosomes. J. Theor. Biol. 132: 203-233.
44. Marshall, C. 1995. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80: 179-185.
45. Massague, J. 1983. Epidermal growth factor-like transforming growth factor II: interaction with epidermal growth factor receptors in human placenta membranes and A431 Cells. J. Biol. Chem. 258: 13614-13620.
46. Masui, H., Wells, A., Lazar, C., Rosenfeld, M. G., Gill, G. N. 1991. Enhanced tumorogenesis of NR6 cells which express non-downregulating epidermal growth factor receptors. Cancer Res. 51: 6170-6175.
47. McGeady, M., Kerby, S., Shankar, V., Ciardiello, F., Salomon, D., Seidman, M. 1989. Infection with a TGFα retroviral vector transforms ordinary mouse mammary epithelial cells but not normal rat fibroblasts. Oncogene 4: 1375-1382.
48. Meyer-Ingold, W. 1993. Wound therapy: growth factors as agents to promote healing. Trends Biotechnol. 11: 387-392.
49. Miller, A. 1990. Progress toward human gene therapy. Blood 76: 271-278.
50. 1H NMR assignments and identification of two antiparallel β-sheets in the solution structure of recombinant hTGFα. Proc. Natl. Acad. Sci. USA 86: 1519-1523.
51. Myrdal, S., Twardzik, D., Auspenberg, N. 1986. Cell-mediated co-action of transforming growth factors: incubation of type β with normal rat kidney cells produces a soluble activity that prolongs the ruffling response to type α. J. Biol. Chem. 102: 1230-1234.
52. Newgard, C. 1994. Cellular engineering and gene therapy strategies for insulin replacement in diabetes. Diabetes 43: 341.
53. Oehrtman, G. 1995. M.S. thesis, University of Illinois at Urbana-Champaign. Urbana, IL, USA.
54. Ogura, H., Tani, K., Ozawa, K., Nagata, S., Asano, S., Takaku, F. 1990. Implantation of the genetically-manipulated fibroblasts into mice as anti-tumor alpha-interferon therapy. Cancer Res. 50: 5102-5106.
55. Palmer, T., Rosman, G., Osborne, W., Miller, A. 1991. Genetically-modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc. Natl. Acad. Sci. USA 88: 1330-1334.
56. Reddy, C., Wells, A., Lauffenburger, D. A. 1994. Proliferative response of fibrobalsts expressing internalization-deficient epidermal growth factor (EGF) receptors is altered via differential EGF depletion effect. Biotechnol. Prog. 10: 377-384.
57. Reddy, C., Wells, A., Lauffenburger, D. A. 1996. EGF- and TGFα-induced mitogenesis: relative potencies are determined by endocytic trafficking effects on ligand availability. J. Cell. Physiol. 166: 512-522.
58. Robinson, C. 1992. Growth factors in wound healing. Trends Biotechnol. 4: 301-302.
59. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809.
60. Schrader, J. 1994. Interleukin-3, pp. 38-40. In: N. Nicola (ed.), Guidebook to cytokines and their receptors. Oxford University Press, New York.
61. Schreiber, A., Winkler, M., Derynck, R. 1986. Transforming growth factor-α: a more potent angiogenic mediator than epidermal growth factor. Science 232: 1250-1253.
62. Schubert, D. 1992. Collaborative interactions between growth factors and the extracellular matrix. Trends Cell Biol. 2: 63-66.
63. Schultz, G., White, M., Mitchell, R., Brown, G., Lynch, J., Twardzik, D., Todaro, G. 1987. Epithelial wound healing enhanced by transforming growth factor-α and vaccinia growth factor. Science 235: 350-352.
64. Selden, R., Skoskiewicz, M., Howie, K., Russell, P., Goodman, H. 1987. Implantation of genetically-engineered fibroblasts into mice: implications for gene therapy. Science 236: 714-718.
65. Smith, J., Derynck, R., Korc, M. 1987. Production of transforming growth factor α in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc. Natl. Acad. Sci. USA 84: 7567-7570.
66. Soler, C., Carpenter, G. 1994. The epidermal growth factor family, pp. 194-197. In: N. Nicola (ed.), Guidebook to cytokines and their receptors. Oxford University Press, New York.
67. Sporn, M., Roberts, A. 1992. Autocrine secretion - 10 years later. Ann. Int. Med. 117: 408-414.
68. St. Louis, D., Verma, I. 1988. An alternative approach to somatic cell gene therapy. Proc. Natl. Acad. Sci. USA 85: 3150-3154.
69. Stern, P., Krieger, N., Nissenson, R., Williams, R., Winkler, M., Derynck, R., Strewler, G. 1985. Human transforming growth factor-alpha stimulates bone resorption in vitro. J. Clin. Invest. 76: 2016-2019.
70. Tadaki, D., Niyogi, S. K. 1993. The functional importance of hydrophobicity of the tyrosine at position 13 of human epidermal growth factor in receptor binding. J. Biol. Chem. 268: 10114-10119.
71. Tani, K., Ozawa, K., Ogura, H., Takahashi, T., Okano, A., Watari, K., Matsudaira, T., Tajika, K., Karasuyama, H., Nagata, S., et al. 1989. Implantation of fibroblasts transfected with human granulocyte-stimulating factor cDNA into mice as a model of cytokine-supplement therapy. Blood 74: 1274-1280.
72. ten Dijke, P., Iwata, K. 1989. Growth factors for wound healing. Bio/Technology 7: 793-797.
73. Traverse, S., Gomez, N., Paterson, H., Marshall, C., Cohen, P. 1992. Sustained activation of the mitogen-activated protein kinase cascade may be required for differentiation of PC 12 cells: comparison of the effects of nerve growth factor and epidermal growth factor. Biochem. J. 288: 351-355.
74. Traverse, S., Seedorf, K., Paterson, H., Marshall, C., Cohen, P., Ullrich, A. 1994. EGF triggers neuronal differentiation of PC 12 cells that overexpress the EGF receptor. Curr. Biol. 4: 694-701.
75. van den Heuvel, M., Nusse, R., Johnston, P., Lawrence, P. 1989. Distribution of the wingless gene product in Drosophila embryos: a protein involved in cell-cell communication. Cell 59: 739-749.
76. Wells, A., Welsh, J., Lazar, C., Wiley, H. S., Gill, G. N., Rosenfeld, M. G. 1990. Ligand-induced transformation by a non-internalizing epidermal growth factor receptor. Science 247: 962-964.
77. Wiley, H. S. 1992. Receptors: topology, dynamics, and regulation, pp. 113-142. In: E. Bittrer (ed.), Membrane dynamics and signaling. JAI Press, Greenwich, CT.
78. Wiley, H. S., Herbst, J. J., Walsh, B. J., Lauffenburger, D. A., Rosenfeld, M. G., Gill, G. N. 1991. The role of tyrosine kinase activity in endocytosis, compartmentation, and downregulation of the EGF receptor. J. Biol. Chem. 266: 11083-11094.
79. Will, B., Lauffenburger, D. A., Wiley, H. S. 1995. Studies on engineered autocrine systems: requirements for ligand release from cells producing an artificial growth factor. Tissue Eng. 1: 81-94.